Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A post-authorization efficacy study to evaluate the long-term efficacy and durability of Ibalizumab (Trogarzo) in combination with other antiretrovirals

Next Previous
X
Search
Trial Profile

A post-authorization efficacy study to evaluate the long-term efficacy and durability of Ibalizumab (Trogarzo) in combination with other antiretrovirals

Status: Planning
Phase of Trial: Phase IV

Latest Information Update: 20 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibalizumab (Primary) ; Antiretrovirals
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms PROMISE

    • Most Recent Events

    • 13 Oct 2021 According to a Theratechnologies media release, the enrollment of patients in this study is expected to begin in in the fourth quarter of 2021.
    • 04 Mar 2021 New trial record
    • 25 Feb 2021 According to a Theratechnologies media release, this study has been requested by EMA in Europe as a post-authorization efficacy study to evaluate the long term efficacy and durability of Trogarzo in combination with other antiretrovirals.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top